Most Recent
A personal injury firm that lost out to a class action heavyweight in a contest to run a case against Toyota unit Hino has dropped its appeal and will wear the costs it incurred in bringing its case.
A judge has rejected AFL great Phil Krakouer’s request for extensive game footage before putting on an amended claim in a racial vilification class action against the league, which is expected to bring five clubs into the proceeding.
Australian wine company McGuigan has lost its bid to trade mark 'Black Label' for its wine after Johnnie Walker, which makes the popular Black Label whiskey, successfully argued it would cause consumer confusion.
Johnson Winter Slattery has expanded its real estate practice, luring an experienced real estate special counsel who has worked at MinterEllison and Holding Redlich.
Buoyed by the recent trial success of CBA and other companies facing shareholder ire, building materials giant Boral is taking its chances at a hearing in a class action alleging disclosure breaches linked to its US windows business.
A judge has signed off on a $230 million settlement of a class action on behalf of thousands of junior doctors who allege they were systemically underpaid by the NSW government.
A tribunal has recommended that a Sydney solicitor be struck from the roll after finding him guilty of professional misconduct for sending numerous profane emails to a Mills Oakley solicitor during a dispute, noting the “unrelenting stream of discourteous, insulting or offensive correspondence” directed to the tribunal.
Contractor Kingfisher Mobile has dropped a claim against Telstra in a $45 million lawsuit alleging the telco breached a November 2022 contract when it engaged a new provider to take over.
The consumer regulator must identify the advertisements it relies on to prove its case against Meta over scam cryptocurrency ads on Facebook, with a judge saying the social media giant should know the case it has to meet.
A GlaxoSmithKline unit has defeated Nova Pharmaceuticals' bid to trade mark 'Novadart' for a generic version of the British company's market-leading drug prostate drug 'Avodart', with a delegate finding the mark would cause consumer confusion.